For: | Artin H, Zisook S, Ramanathan D. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World J Psychiatr 2021; 11(6): 201-214 [PMID: 34168967 DOI: 10.5498/wjp.v11.i6.201] |
---|---|
URL: | https://www.wjgnet.com/2220-3206/full/v11/i6/201.htm |
Number | Citing Articles |
1 |
Carina S Peritore. The Promise of Psychedelic Research. Future Drug Discovery 2022; 4(1) doi: 10.4155/fdd-2021-0012
|
2 |
Christiane Martins de Vasconcellos Silveira, Vanessa Farelo dos Santos, Isis Moraes Ornelas, Beatriz de Sá Carrilho, Matheus Antonio Vieira de Castro Ventura, Henrique Marcelo Gualberto Pereira, Stevens Kastrup Rehen, Magno Junqueira. Systematic characterization of Lysergic Acid Diethylamide metabolites in Caenorhabditis elegans by ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry. Journal of Chromatography A 2023; 1708: 464362 doi: 10.1016/j.chroma.2023.464362
|
3 |
Lynette A. Desouza, Madhurima Benekareddy, Sashaina E. Fanibunda, Farhan Mohammad, Balaganesh Janakiraman, Utkarsha Ghai, Tamar Gur, Julie A. Blendy, Vidita A. Vaidya. The Hallucinogenic Serotonin2A Receptor Agonist, 2,5-Dimethoxy-4-Iodoamphetamine, Promotes cAMP Response Element Binding Protein-Dependent Gene Expression of Specific Plasticity-Associated Genes in the Rodent Neocortex. Frontiers in Molecular Neuroscience 2021; 14 doi: 10.3389/fnmol.2021.790213
|
4 |
Kwonmok Ko, Emma I. Kopra, Anthony J. Cleare, James J. Rucker. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders 2023; 322: 194 doi: 10.1016/j.jad.2022.09.168
|
5 |
Hewa Artin, Sean Bentley, Eamonn Mehaffey, Fred X. Liu, Kevin Sojourner, Andrew W. Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon De Peralta, Dewleen G. Baker, Jyoti Mishra, Dhakshin Ramanathan. Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series. eClinicalMedicine 2022; 48: 101439 doi: 10.1016/j.eclinm.2022.101439
|
6 |
Noémi Császár-Nagy, Petr Bob, István Bókkon. A Multidisciplinary Hypothesis about Serotonergic Psychedelics. Is it Possible that a Portion of Brain Serotonin Comes From the Gut?. Journal of Integrative Neuroscience 2022; 21(5) doi: 10.31083/j.jin2105148
|
7 |
Matthew B. Wall, Rebecca Harding, Rayyan Zafar, Eugenii A. Rabiner, David J. Nutt, David Erritzoe. Neuroimaging in psychedelic drug development: past, present, and future. Molecular Psychiatry 2023; 28(9): 3573 doi: 10.1038/s41380-023-02271-0
|
8 |
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, Josimar Hernandez Antonio, Philip A. Bonanno, Carolyn MacLeod, Charlotte Pierce, Hunter Carney, Morgan T. Morrison, Charles Saylor, George Danias, Lauren Lepow, Rachel Yehuda. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Current Neuropharmacology 2024; 22(4): 636 doi: 10.2174/1570159X22666231027111147
|
9 |
Hannah N. Saeger, David E. Olson. Psychedelic‐inspired approaches for treating neurodegenerative disorders. Journal of Neurochemistry 2022; 162(1): 109 doi: 10.1111/jnc.15544
|
10 |
Christianne E. Strang. Art therapy and neuroscience: evidence, limits, and myths. Frontiers in Psychology 2024; 15 doi: 10.3389/fpsyg.2024.1484481
|
11 |
David E. Olson. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry 2022; 61(3): 127 doi: 10.1021/acs.biochem.1c00812
|
12 |
María Marcela Velásquez Toledo. Evidencias y perspectivas del potencial antidepresivo del “alcaloide mágico” psilocibina: una revisión narrativa. Cultura y Droga 2023; 28(35): 91 doi: 10.17151/culdr.2023.28.35.5
|
13 |
Alexandria N. Tartt, Madeline B. Mariani, Rene Hen, J. John Mann, Maura Boldrini. Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications. Molecular Psychiatry 2022; 27(6): 2689 doi: 10.1038/s41380-022-01520-y
|
14 |
Nina Hartter, Marvin Däumichen, Andrea Jungaberle, Christopher Schmidt, Max Wolff, Gerhard Gründer, Henrik Jungaberle. Einstellungen zur Einführung der psychedelischen Therapie. Nervenheilkunde 2024; 43(06): 357 doi: 10.1055/a-2283-0238
|
15 |
Alexander Pilozzi, Simmie Foster, David Mischoulon, Maurizio Fava, Xudong Huang. A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression. International Journal of Molecular Sciences 2023; 24(15): 12513 doi: 10.3390/ijms241512513
|
16 |
Hewa Artin, Sean Bentley, Eamonn Mehaffey, Fred X. Liu, Kevin Sojourner, Andrew Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon De Peralta, Dewleen G. Baker, Jyoti Mishra, Dhakshin Ramanathan. Effects of Intranasal (S)-Ketamine on Veterans With Co-Morbid Treatment-Resistant Depression and PTSD. SSRN Electronic Journal 2021; doi: 10.2139/ssrn.3928508
|
17 |
Erika Plazas, Nicoletta Faraone. Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents. Biomedicines 2023; 11(2): 461 doi: 10.3390/biomedicines11020461
|
18 |
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, Christopher S. Stauffer. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022; 239(6): 1945 doi: 10.1007/s00213-022-06083-y
|
19 |
Manon van den Berg, Igor Magaraggia, Rudy Schreiber, Todd M. Hillhouse, Joseph H. Porter. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. Psychopharmacology 2022; 239(6): 1853 doi: 10.1007/s00213-022-06106-8
|